Research from e27, e27

Research from e27

e27 is Asia's largest Tech media platform. We cover the latest news on emerging and disruptive businesses across the region.

Private Capital Markets

KYAN Therapeutics / Private Capital Markets

<ul><li>From drug development to personalised medicine, KYAN Therapeutics offers a solution to identify the optimal outcome for millions of possible drug-dose combinations</li><li>Singapore-based KYAN Therapeutics, a biotech company with novel personalised medicine and drug-dose combination optimisation technology, has closed a US$5 million oversubscribed pre-Series A funding round.</li><li>KYAN will use the funds to advance clinical development, expand lab infrastructure and treat more patients globally.</li></ul><div><p></p></div>

From drug development to personalised medicine, KYAN Therapeutics offers a solution to identify the optimal outcome for millions of possible drug-dose combinationsSingapore-based KYAN Therapeutics, a biotech company with novel personalised medicine and drug-dose combination optimisation technology, has closed a US$5 million oversubscribed pre-Series A funding round.KYAN will use the funds to advance clinical development, expand lab infrastructure and treat more patients globally.

KYAN Therapeutics Bags US$5M to Bridge the Cancer Care Gap Using Tech

Singapore

KYAN Therapeutics, Inc. is a biotechnology company. The Company tackles the complexity of cancer by combining small data AI and biological experiments. KYAN Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

KYAN Therapeutics (2198779D US)

KYAN Therapeutics Bags US$5M to Bridge the Cancer Care Gap Using Tech

From drug development to personalised medicine, KYAN Therapeutics offers a solution to identify the optimal outcome for millions of possible drug...

e27

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)